Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : drives awareness and scientific discussion around lungworm -- Greater need to better understand the prevalence of lungworm in European countries / Scientific experts discuss prevention, infection, and persistence of lungworm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:25pm CET

Copenhagen (Denmark), October 5, 2017- Snails can explore the length of an average British garden in a single night, reaching a top speed of one meter per hour. They may seem like harmless creatures at first sight, but snails and slugs are quickly becoming a strong threat to the health and well-being of dogs. More and more dog owners have recently become aware of a disease which has been diagnosed more frequently over the last years throughout many European countries - Angiostrongylus vasorum (Lungworm/ French Heartworm).

Lungworm, or French Heartworm, is a disease spread by parasitic nematodes that can cause angiostrongylosis, a serious illness in dogs and other canine species. The parasite can be carried by slugs and snails and infect animals. The disease has not been shown to transmit to humans and is not considered a zoonotic disease. However, it was a topic of intense discussion and debate at the 42World Small Animal Veterinary Association (WSAVA) Congress in Copenhagen, Denmark.

The WSAVA hosts a veterinary congress once a year for companion animal veterinarians from across the globe. It is an internationally recognized veterinary congress with a scientific program.

Bayer Animal Health organized a continuing professional development for veterinarians and key opinion leaders entitled 'NEW UPDATES ON ANGIOSTRONGYLUS VASORUM IN EUROPE'. A panel of veterinary parasitology experts shared some insights on this topic.

Dr. Eric Morgan, MA, VetMB, PhD, BA, MRCVS UK, University of Bristol, Veterinary Parasitology and Ecology
'Lungworm infection used to be a rare disease in few European countries. However, we have had more cases recently in many European countriesso it is on the increase. For the UK and Germany there is now evidence that it is spreading. Spread of the disease is likely through infected dogs and foxes and via slugs and snails.'

Dr. Roland Schaper, Dr. med. vet, Bayer Animal Health GmbH, Global Veterinary Scientific Affairs Manager, Germany
'Treatment of an existing
A. vasoruminfection should be the last resort, due to the severity of the disease. Prevention of this potentially fatal disease with regular treatment is a good approach. But the best approach to avoid any parasite development completely is true infection prevention.'

While the lungworm is recognized as a major threat in the United Kingdom and the Nordics, it still seems to be underestimated in other European countries such as France, Germany and the Benelux. For the United Kingdom and Germany there is new evidence that it is spreading.

'This also demonstrates the importance of continuous training for veterinarians,' says Dr. Markus Edingloh, Global Head of Veterinary Scientific Affairs at Bayer Animal Health. 'Therefore, Bayer Animal Health is proud to support veterinarians with continuing professional development about the latest information and techniques. We want to emphasize the importance of fighting Angiostrongylus vasorumand draw attention to the fact that prevention plays an essential role in keeping our animals healthy.'

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.

Bayer AG published this content on 05 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 October 2017 10:24:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
04:18p BAYER : rivaroxaban submitted to U.S. FDA for approval in patients with coronary..
10:09aDJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
12/12 Monsanto offers cash to U.S. farmers who use controversial chemical
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 BAYER : Preventive Maintenance & service solution on existing Bayer/Medrad and A..
12/08 BAYER : J-- Preventive Maintenance & service solution on existing Bayer/Medrad a..
12/08 'Right steps' point to a healthier China
12/07 BAYER : Research Conducted at Bayer Has Provided New Information about Atrial Fi..
12/07 BAYER : Findings from Bayer Has Provided New Data on Liver Cancer (Exposure-resp..
12/07 BAYER : New Findings from Bayer in Antibiotics Provides New Insights (Physiologi..
More news
News from SeekingAlpha
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/08 BLOOMBERG : Bayer to face EU objections to Monsanto deal in coming days
12/07 COBAS ASSET MANAGEMENT : Comments On Third Quarter 2017
12/06 You Get A Dilution! You Get A Dilution! What About CRISPR Therapeutics?
12/05 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 5, 2017
Financials (€)
Sales 2017 35 698 M
EBIT 2017 7 647 M
Net income 2017 6 050 M
Debt 2017 8 890 M
Yield 2017 2,47%
P/E ratio 2017 14,05
P/E ratio 2018 18,38
EV / Sales 2017 2,72x
EV / Sales 2018 2,48x
Capitalization 88 194 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 121 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER5.62%102 387
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659